RayKnowChina Research Map
Shortlist

RecruitingBreast cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

Dalpiciclib Plus Toremifene for First-line Advanced HR Positive and HER2 Negative Breast Cancer

An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Tianjin Medical University Cancer Institute & Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06495515, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 75 years; sex: women only

    Registered eligibility fields

  2. Patients with negative serum pregnancy test and potential fertility must agree to use it during treatment and on the last attempt Use effective non hormonal contraceptive methods for at least 12 months after the trial drug.

    Inclusion criterion 11

    Previously used any CDK inhibitors, tamoxifen, everolimus, or drugs that inhibit the PI3K mTOR pathway for treatment. Using strong or moderate CYP3A4 and/or CYP2D6 inhibitors or inducers.

    Exclusion criterion 5

  3. ECOG PS 0-1;

    Inclusion criterion 2

  4. TBIL≤1.5×ULN; ALT and AST ≤ 2 × ULN;

    Inclusion criterion 7

    BUN and Cr ≤ 1.5 × ULN with creatinine clearance rate ≥ 50 mL/min (Cockcroft Gault formula);

    Inclusion criterion 8

  5. The previous pathological diagnosis was HER2 positive breast cancer.

    Exclusion criterion 1

    The patient has undergone major surgical procedures unrelated to breast cancer within 4 weeks before enrollment, or has not fully recovered from such surgical procedures.

    Exclusion criterion 3

    Other malignant tumors within the past 5 years, excluding cured cervical carcinoma in situ, basal cell carcinoma of the skin, or squamous cell carcinoma of the skin.

    Exclusion criterion 6

  6. Pregnant and lactating female patients, female patients with fertility and positive baseline pregnancy test results, or those in the whole family Female patients of childbearing age who were unwilling to take effective contraceptive measures during the trial period.

    Exclusion criterion 10

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06495515, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Postmenopausal or premenopausal/perimenopausal female patients aged ≥ 18 years and ≤ 75 years old,

Meet one of the following conditions:

a) Previously underwent bilateral oophorectomy, or aged ≥ 60 years old; or b) Age\<60, natural postmenopausal state (defined as spontaneous cessation of regular menstruation for at least 12 consecutive months without any other pathological or physiological reasons), E2 and FSH at postmenopausal levels.

c) Premenopausal or perimenopausal female patients can also be selected, but they must be willing to receive LHRH agonist treatment during the study period.

  • ECOG PS 0-1;
  • Female breast cancer patients diagnosed as HR positive and HER2 negative by pathology have evidence of local recurrence or metastasis, which is not suitable for surgical resection or radiotherapy for the purpose of cure.

It has been diagnosed as HR positive and HER2 negative breast cancer (ER and PR ≥ 10%)

HER2 is negative. If HER2 is expressed as 2+, in situ hybridization testing is required to confirm that the HER2 gene has not been amplified; 4. The patient\'s previous endocrine therapy must meet the following conditions:

A) Late stage: did not receive any endocrine therapy; Progression within 12 months of receiving other endocrine treatments (except tamoxifen) in the late stage; b) Stage of adjuvant endocrine therapy: Progress over 12 months after completion of tamoxifen assisted endocrine therapy; During the use of aromatase inhibitors (treatment duration exceeding 6 months) or after completion of treatment, progress may occur.

According to the RECIST 1.1 standard, there should be at least one measurable lesion present or only bone metastases (including osteolytic lesions or mixed osteolytic/osteogenic lesions).

  • The functional level of organs must meet the following requirements:
  • Blood routine

•ANC≥1.5×109/L;

•PLT≥90×109/L;

•Hb≥90 g/L;

  • Blood biochemistry
  • TBIL≤1.5×ULN; ALT and AST ≤ 2 × ULN;
  • BUN and Cr ≤ 1.5 × ULN with creatinine clearance rate ≥ 50 mL/min (Cockcroft Gault formula);
  • Cardiac color Doppler ultrasound

•LVEF≥50%;

  • 12 lead electrocardiogram The QT interval (QTcF) corrected by the Fridericia method is\<470 ms for females.
  • Patients with negative serum pregnancy test and potential fertility must agree to use it during treatment and on the last attempt Use effective non hormonal contraceptive methods for at least 12 months after the trial drug.
  • Voluntarily participate in this study, sign informed consent, have good compliance, and are willing to cooperate with follow-up.

Exclusion Criteria:

  • The previous pathological diagnosis was HER2 positive breast cancer.
  • Researchers determine patients who are not suitable for endocrine therapy. This includes late stage patients who have symptoms, have spread to the internal organs, and are at risk of life-threatening complications in the short term (including patients with uncontrollable exudates (chest, pericardium, abdominal cavity) through drainage or other methods, pulmonary lymphangitis, and more than 50% liver involvement).
  • The patient has undergone major surgical procedures unrelated to breast cancer within 4 weeks before enrollment, or has not fully recovered from such surgical procedures.
  • Patients with extensive advanced/metastatic, symptomatic visceral diseases, or known uncontrolled or symptomatic brain metastases.
  • Previously used any CDK inhibitors, tamoxifen, everolimus, or drugs that inhibit the PI3K mTOR pathway for treatment. Using strong or moderate CYP3A4 and/or CYP2D6 inhibitors or inducers.
  • Other malignant tumors within the past 5 years, excluding cured cervical carcinoma in situ, basal cell carcinoma of the skin, or squamous cell carcinoma of the skin.
  • Have suffered from any heart disease, including: (1) angina pectoris; (2) Arrhythmias that require medication treatment or have clinical significance; (3) Myocardial infarction; (4) Heart failure; (5) Any other heart disease determined by the researcher as unsuitable for participation in this trial.
  • Inability to swallow, intestinal obstruction, or other factors that affect medication administration and absorption.
  • Known to be allergic to darcilib, letrozole, or any excipients.
  • Pregnant and lactating female patients, female patients with fertility and positive baseline pregnancy test results, or those in the whole family Female patients of childbearing age who were unwilling to take effective contraceptive measures during the trial period.
  • Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.
  • Other serious physical or mental illnesses or laboratory test abnormalities may increase the risk of participating in the study, or Disturb the research results and any other circumstances that the researcher deems unsuitable for participation in this study.

Quoted from ClinicalTrials.gov, NCT06495515, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06495515, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06495515